Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience
Abstract
:1. Introduction
2. Materials and Methods
2.1. Population
2.2. Objectives
2.3. Biological Therapies Considered
- Ixekizumab (80 mg) fl sc every 4 weeks;
- Secukinumab (150 mg) 2 fl sc every 4 weeks;
- Brodalumab (210 mg) fl sc every 2 weeks;
- Guselkumab (100 mg) fl sc every 8 weeks;
- Risankizumab (75 mg) 2 fl sc every 12 weeks (150 mg fl was not available during the the study);
- Tildrakizumab (100 mg) fl sc every 12 weeks.
2.4. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Dapavo, P.; Siliquini, N.; Mastorino, L.; Avallone, G.; Merli, M.; Agostini, A.; Cariti, C.; Viola, R.; Stroppiana, E.; Verrone, A.; et al. Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: A retrospective study. J. Dermatolog. Treat. 2022, 33, 2352–2357. [Google Scholar] [CrossRef] [PubMed]
- Armstrong, A.W.; Read, C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA 2020, 323, 1945–1960. [Google Scholar] [CrossRef] [PubMed]
- Nast, A.; Smith, C.; Spuls, P.I.; Avila Valle, G.; Bata-Csörgö, Z.; Boonen, H.; De Jong, E.; Garcia-Doval, I.; Gisondi, P.; Kaur-Knudsen, D.; et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris—Part 1: Treatment and monitoring recommendations. J. Eur. Acad. Dermatol. Venereol. 2020, 34, 2461–2498. [Google Scholar] [CrossRef] [PubMed]
- Mastorino, L.; Burzi, L.; Frigatti, G.; Fazio, A.; Celoria, V.; Macagno, N.; Rosset, F.; Passerini, S.G.; Roccuzzo, G.; Verrone, A.; et al. Clinical effectiveness of IL-17 and IL-23 inhibitors on difficult-to-treat psoriasis areas (scalp, genital, and palmoplantar sites): A retrospective, observational, single-center, real-life study. Expert Opin. Biol. Ther. 2023, 23, 929–936. [Google Scholar] [CrossRef] [PubMed]
- Chiricozzi, A.; Romanelli, P.; Volpe, E.; Borsellino, G.; Romanelli, M. Scanning the Immunopathogenesis of Psoriasis. Int. J. Mol. Sci. 2018, 19, 179. [Google Scholar] [CrossRef] [PubMed]
- Mastorino, L.; Dapavo, P.; Avallone, G.; Merli, M.; Cariti, C.; Rubatto, M.; Pala, V.; Quaglino, P.; Ribero, S. Biologic treatment for psoriasis in cancer patients: Should they still be considered forbidden? J. Dermatolog. Treat. 2022, 33, 2495–2502. [Google Scholar] [CrossRef] [PubMed]
- Mastorino, L.; Dapavo, P.; Trunfio, M.; Avallone, G.; Rubatto, M.; Calcagno, A.; Ribero, S.; Quaglino, P. Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy. Acta Derm. Venereol. 2022, 102, adv00821. [Google Scholar] [CrossRef]
- Blauvelt, A.; Chiricozzi, A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin. Rev. Allergy Immunol. 2018, 55, 379–390. [Google Scholar] [CrossRef]
- Chiricozzi, A.; Saraceno, R.; Chimenti, M.S.; Guttman-Yassky, E.; Krueger, J.G. Role of IL-23 in the pathogenesis of psoriasis: A novel potential therapeutic target? Expert Opin. Ther. Targets 2014, 18, 513–525. [Google Scholar] [CrossRef]
- Roccuzzo, G.; Mastorino, L.; Susca, S.; Cariti, C.; Passerini, S.G.; Sciamarrelli, N.; Borriello, S.; Macagno, N.; Sliquini, N.; Avallone, G.; et al. Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: A comparative study on different agents. Clin. Exp. Dermatol. 2023, 48, 379–381. [Google Scholar] [CrossRef]
- Mastorino, L.; Susca, S.; Cariti, C.; Sliquini, N.; Verrone, A.; Stroppiana, E.; Ortoncelli, M.; Dapavo, P.; Ribero, S.; Quaglino, P. Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients. J. Eur. Acad. Dermatol. Venereol. 2023, 37, 1848–1853. [Google Scholar] [CrossRef] [PubMed]
- Chiricozzi, A.; Conti, A.; Burlando, M.; Odorici, G.; Gaiani, F.; Panduri, S.; Malagoli, P. Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience. Dermatology 2019, 235, 213–218. [Google Scholar] [CrossRef] [PubMed]
- Damiani, G.; Conic, R.R.Z.; de Vita, V.; Costanzo, A.; Regazzini, R.; Pigatto, P.D.M.; Bragazzi, N.L.; Pacifico, A.; Malagoli, P. When IL-17 inhibitors fail: Real-life evidence to switch from secukinumab to adalimumab or ustekinumab. Dermatol. Ther. 2019, 32, e12793. [Google Scholar] [CrossRef] [PubMed]
- Mastorino, L.; Dapavo, P.; Susca, S.; Cariti, C.; Siliquini, N.; Verrone, A.; Stroppiana, E.; Ortoncelli, M.; Quaglino, P.; Ribero, S. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment. J. Dtsch. Dermatol. Ges. 2023; epub ahead of print. [Google Scholar] [CrossRef]
- Revu, S.; Wu, J.; Henkel, M.; Rittenhouse, N.; Menk, A.; Delgoffe, G.M.; Poholek, A.C.; McGeachy, M.J. IL-23 and IL-1β Drive Human Th17 Cell Differentiation and Metabolic Reprogramming in Absence of CD28 Costimulation. Cell Rep. 2018, 22, 2642–2653. [Google Scholar] [CrossRef] [PubMed]
- Mastorino, L.; Roccuzzo, G.; Dapavo, P.; Siliquini, N.; Avallone, G.; Rubatto, M.; Quaglino, P.; Ribero, S. Switching from IL23 inhibitors to IL17 inhibitors: A safe and effective practice? Dermatol. Ther. 2022, 35, e15697. [Google Scholar] [CrossRef] [PubMed]
- Caposiena Caro, R.D.; Pensa, C.; Lambiase, S.; Candi, E.; Bianchi, L. Risankizumab effectiveness in a recalcitrant case of hidradenitis suppurativa after anti-TNF and anti-interleukin-17 failures. Dermatol. Ther. 2021, 34, e15116. [Google Scholar] [CrossRef]
- Blauvelt, A.; Kimball, A.B.; Augustin, M.; Okubo, Y.; Witte, M.M.; Capriles, C.R.; Sontag, A.; Arora, V.; Osuntokun, O.; Strober, B. Efficacy and safety of mirikizumab in psoriasis: Results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1). Br. J. Dermatol. 2022, 187, 866–877. [Google Scholar] [CrossRef]
- Gargiulo, L.; Ibba, L.; Pavia, G.; Vignoli, C.A.; Piscazzi, F.; Valenti, M.; Sanna, F.; Perugini, C.; Avagliano, J.; Costanzo, A.; et al. Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study. Dermatol. Ther. 2022, 12, 2309–2324. [Google Scholar] [CrossRef]
- Mastorino, L.; Castelli, F.; Stroppiana, E.; Verrone, A.; Ortoncelli, M.; Susca, S.; Boskovic, S.; Passerini, S.; Macagno, N.; Cariti, C.; et al. Risankizumab shows faster response in bio naïve than in bio-experienced psoriatic patients. J. Eur. Acad. Dermatol. Venereol. 2022, 36, e838–e841. [Google Scholar] [CrossRef]
- Mastorino, L.; Siliquini, N.; Avallone, G.; Zenone, M.; Ortoncelli, M.; Quaglino, P.; Dapavo, P.; Ribero, S. Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study. Dermatol. Ther. 2022, 35, e15670. [Google Scholar] [CrossRef]
- Bonifati, C.; Morrone, A.; Cristaudo, A.; Graceffa, D. Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience. Dermatol. Ther. 2021, 34, e14584. [Google Scholar] [CrossRef] [PubMed]
- Megna, M.; Fabbrocini, G.; Ruggiero, A.; Cinelli, E. Efficacy and safety of risankizumab in psoriasis patients who failed anti-IL-17, anti-12/23 and/or anti IL-23: Preliminary data of a real-life 16-week retrospective study. Dermatol. Ther. 2020, 33, e14144. [Google Scholar] [CrossRef] [PubMed]
- Hung, Y.T.; Lin, Y.J.; Chiu, H.Y.; Huang, Y.H. Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: A real-world practice. Ther. Adv. Chronic Dis. 2021, 12, 20406223211046685. [Google Scholar] [CrossRef] [PubMed]
- Chiang, C.Y.; Tsai, T.F. Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab. Dermatol. Ther. 2021, 11, 301–306. [Google Scholar] [CrossRef]
- Yiu, Z.Z.N.; Becher, G.; Kirby, B.; Laws, P.; Reynolds, N.J.; Smith, C.H.; Warren, R.B.; Griffiths, C.E.M.; Browne, F.; Evans, I.; et al. Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis. JAMA Dermatol. 2022, 158, 1131–1141, Erratum in JAMA Dermatol. 2022, 158, 1461. [Google Scholar] [CrossRef]
- Gisondi, P.; Talamonti, M.; Chiricozzi, A.; Piaserico, S.; Amerio, P.; Balato, A.; Bardazzi, F.; Pinton, P.C.; Campanati, A.; Cattaneo, A.; et al. Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. Dermatol. Ther. 2021, 11, 235–252. [Google Scholar] [CrossRef]
Switched Patients (48) | General Psoriatic Population (590) | p-Value | |
---|---|---|---|
Sex (F/M) | 36.7% | 35.7% | 0.659 |
Age (mean) | 56.5 (SD 13) | 54.7 (SD 15.6) | 0.429 |
Age of onset (mean) | 35.7 (SD 16.5) | 35.65 (16 SD) | 0.819 |
PSA (yes/no) | 16.7% | 26.9% | 0.117 |
BMI (mean) | 27.2 (SD 5.3) | 27 (SD 5.6) | 0.225 |
Obesity (yes/no) | 18.8% | 18.8% | 0.985 |
Cardiovascular disease (yes/no) | 65.7% | 44% | 0.024 |
Diabetes mellitus (yes/no) | 11.4% | 12.7% | 0.688 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Giordano, S.; Dapavo, P.; Ortoncelli, M.; Stroppiana, E.; Verrone, A.; Quaglino, P.; Ribero, S.; Mastorino, L. Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience. J. Clin. Med. 2023, 12, 7503. https://doi.org/10.3390/jcm12247503
Giordano S, Dapavo P, Ortoncelli M, Stroppiana E, Verrone A, Quaglino P, Ribero S, Mastorino L. Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience. Journal of Clinical Medicine. 2023; 12(24):7503. https://doi.org/10.3390/jcm12247503
Chicago/Turabian StyleGiordano, Silvia, Paolo Dapavo, Michela Ortoncelli, Elena Stroppiana, Anna Verrone, Pietro Quaglino, Simone Ribero, and Luca Mastorino. 2023. "Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience" Journal of Clinical Medicine 12, no. 24: 7503. https://doi.org/10.3390/jcm12247503